Conatus Pharma (CNAT) became Histogen (HSTO) via reverse merger

• Jan 2020: After its Novartis-partnered nonalcoholic steatohepatitis (NASH) drug failed a third midphase trial, Conatus Pharma (CNAT) unveiled a plan to lay off 40% of its staffers. Then the company has found its lifeline—a reverse merger with regenerative medicine player Histogen (HSTO).